Kiadis' Reviroc to progress to Ph III trials

USA-based Kiadis has completed a Phase II clinical trial evaluating Reviroc, a drug used to eliminate cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. Data from the study revealed improved overall survival of Reviroc-treated patients, the firm stated, adding that the results allow it to prepare for a Phase III clinical study.

In the non-randomized open-label study, 25 patients, each of whom had reached end-stage non-Hodgkin's lymphoma, were treated at multiple centers in Canada. The objective of the study was to determine the safety of the Reviroc treatment and its ability to eliminate cancer cells from a contaminated graft. Reviroc-treated grafts all showed excellent engraftment, indicating that the agent does not negatively impact the graft itself.

The Reviroc clinical trial data was evaluated against a historical control group from the Center for International Blood and Marrow Transplant Research of patients who had received an autologous transplant without the drug. According to the results, treated patients had an 80% chance of survival at three years post transplantation, while the CIBMTR control group had a 55% chance of survival.